A new study conducted by a team of Washington, DC mesothelioma surgeons finds that peritoneal mesothelioma patients who have a combination of cytoreductive surgery and heated chemotherapy (CRS/HIPEC) again when cancer comes back have better outcomes and few serious complications.

Mesothelioma surgeon Dr. Paul Sugarbaker and colleagues with the Program in Peritoneal Surface Oncology analyzed the outcomes of 205 consecutive CRS/HIPEC procedures for mesothelioma, 44 of which were repeat procedures.

“Iterative [repeat] CRS and HIPEC can be performed safely and appear to have benefits with this group of patients showing an improved median survival,” writes Dr. Sugarbaker’s colleague and lead author on the study, Chukwuemeka Ihemelandu, MD.

The study, published in the Annals of Surgical Oncology, found a complication rate among repeat CRS/HIPEC patients of just 2.3% and no deaths within 30 days of surgery.

“We know that CRS and HIPEC can improve survival in peritoneal mesothelioma, but we also know that, in almost all cases, that cancer will start growing again,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “This study is potentially very good news for patients in that situation.”

To read the study and its findings in full please, see ‘Repeat CRS/HIPEC Improves Survival for Peritoneal Mesothelioma’ now available on the Surviving Mesothelioma website.

If you or a family member have been affected by mesothelioma please contact us today on Freephone 0800 294 3065, or talk to us on live chat where we will be happy to answer any questions you may have.